Sanofi says phase 3 studies show amlitelimab improves atopic dermatitis at Week 24

Reuters03-28 23:00
<a href="https://laohu8.com/S/GCVRZ">Sanofi</a> says phase 3 studies show amlitelimab improves atopic dermatitis at Week 24
  • Sanofi reported new phase 3 results for amlitelimab in moderate-to-severe atopic dermatitis, presented in a late-breaking session at 2026 American Academy of Dermatology Annual Meeting.
  • COAST 1 met primary endpoint at Week 24, with vIGA-AD 0/1 rates of 21.1% on Q4W dosing or 22.5% on Q12W dosing versus 9.2% on placebo.
  • COAST 2 also met primary endpoint at Week 24, with vIGA-AD 0/1 rates of 25.3% on Q4W dosing or 25.7% on Q12W dosing versus 14.8% on placebo.
  • SHORE trial, which combined amlitelimab with topical therapies, showed Week 24 vIGA-AD 0/1 rates of 28.7% on Q4W dosing or 32.3% on Q12W dosing versus 16.8% on placebo.
  • Sanofi highlighted progressively increasing efficacy through Week 24 with no plateau signal, supporting potential Q12W dosing from treatment start, with ESTUARY phase 3 extension results expected in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603281100OMX_____CNEWS_EN_GNW1001172787_en) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment